8-K: Windtree Secures Convertible Note for CommLoan Acquisition

Windtree Therapeutics issued $857,142.86 in senior convertible promissory notes to fund an acquisition and general corporate purposes.

Summary

• Windtree Therapeutics, Inc. issued senior convertible promissory notes (2026 Notes) with a principal amount of $857,142.86 to an institutional investor on November 25, 2025.
• The company received a funded amount of $600,000 from this issuance.
• The 2026 Notes mature on November 26, 2026, and bear interest at 10% per annum, payable monthly in arrears on the 5th calendar day.
• Proceeds from the notes are allocated with $450,000 advanced to CommLoan Inc. for a potential acquisition and $150,000 retained for general corporate purposes.
• Mandatory prepayment is required for 25% of gross proceeds from a Common Stock Purchase Agreement dated June 26, 2024, with a 115% premium.
• If the company completes a qualified equity financing of $1,000,000 or more, the notes must be repaid in full with a 115% premium on the original note value.
• The notes are convertible at the holder's option into common stock at a conversion price equal to 90% of the lowest sale price for the 20 consecutive trading days preceding conversion.
• A beneficial ownership limitation of 4.99% (increasable to 9.99% with 61 days notice) applies to conversions.
• The company must file an S-1 resale registration statement within 45 calendar days following November 25, 2025.
• The conversion price will be reduced if the company issues common stock or equivalents at a lower effective price (Dilutive Issuance).
• The holder has rollover rights, allowing them to apply principal and interest as purchase consideration in future equity/debt offerings at 80% of the cash purchase price.
• Events of Default, including non-payment, covenant breaches, bankruptcy, and change of control, can trigger acceleration at 120% of the unpaid principal balance plus accrued interest.
• The holder is entitled to a $1,500 review fee for each conversion of the note.

Sentiment

Score: 2

Explanation: The terms of this financing are highly unfavorable to the company and its existing shareholders, indicating a significant need for capital under challenging conditions. The high interest rate, substantial dilution potential from the conversion terms, and punitive default provisions suggest financial distress or a very weak bargaining position.

Positives

• Secured $600,000 in funding, providing immediate capital for operations and strategic initiatives.
• The financing facilitates the potential acquisition of CommLoan Inc., indicating a strategic growth move.
• The rollover rights provide the note holder with flexibility to participate in future financings, potentially simplifying future capital raises for the company.

Negatives

• The funded amount of $600,000 is significantly less than the principal amount of $857,142.86, implying a substantial original issue discount or high fees.
• The 10% annual interest rate is high, increasing the cost of debt for the company.
• The conversion price is set at 90% of the lowest sale price over 20 trading days, which is highly dilutive for existing shareholders.
• Significant prepayment premiums of 115% apply to both mandatory prepayments and qualified financing prepayments, making early repayment costly.
• Events of Default trigger acceleration at 120% of outstanding principal plus an additional 1.5% monthly interest (18% annually), imposing severe penalties.
• The holder's rollover rights allow participation in future financings at an 80% discount, further disadvantaging existing shareholders.

Risks

• Dilution Risk: The discounted conversion price (90% of lowest 20-day sale price) and dilutive issuance provisions pose a significant risk of dilution for existing shareholders.
• Financial Distress Risk: The high interest rate, substantial prepayment premiums, and punitive default terms suggest the company is taking on financing under unfavorable conditions, indicating potential financial vulnerability.
• Liquidity Risk: Mandatory prepayment clauses, including 25% of proceeds from a prior stock purchase agreement and full repayment upon a $1M+ qualified financing, could strain the company's cash flow.
• Operational Risk: Failure to file the S-1 resale registration statement within 45 days constitutes an Event of Default, triggering severe penalties.
• Acquisition Risk: The notes are issued in connection with a letter of intent to acquire CommLoan Inc., introducing integration and performance risks associated with mergers and acquisitions.
• Market Price Volatility Risk: The conversion price being tied to the lowest sale price over 20 trading days could incentivize the holder to convert during periods of price decline, potentially exacerbating downward pressure on the stock.

Future Outlook

The company intends to use $450,000 of the proceeds as an advance to CommLoan Inc. in connection with a letter of intent to acquire all of its issued and outstanding securities, signaling a strategic move towards M&A. The remaining $150,000 is designated for general corporate purposes.

Industry Context

This financing, characterized by high interest rates, significant dilution potential, and punitive default terms, is typical for smaller, high-risk companies, particularly those in the biotechnology or pharmaceutical sector (like Windtree Therapeutics) that may have limited access to conventional financing. The planned acquisition of CommLoan Inc. suggests a strategic expansion or diversification, but the unfavorable financing terms indicate a challenging capital environment for the company.

Comparison to Industry Standards

• The 10% interest rate on senior convertible notes is significantly higher than rates typically offered to established, financially stable companies, but can be common for micro-cap or development-stage firms with higher risk profiles.
• The conversion price, set at 90% of the lowest sale price over 20 trading days, is a 'toxic' or 'death spiral' financing feature, highly dilutive to existing shareholders and generally considered far below industry best practices for healthy companies.
• Prepayment premiums of 115% are exceptionally high, indicating a substantial cost of capital and a strong negotiating position for the investor.
• The beneficial ownership limitation of 4.99% (increasable to 9.99%) is a standard provision to manage regulatory filing requirements for the noteholder.
• The requirement to file an S-1 resale registration statement within 45 days is standard for private placements of convertible securities, ensuring liquidity for the investor.
• Rollover rights allowing the holder to participate in future financings at an 80% discount are highly favorable to the investor and further disadvantage existing shareholders, reflecting the company's urgent need for capital.

Related Party Transactions

• The filing mentions a mandatory prepayment tied to a Common Stock Purchase Agreement dated June 26, 2024, by and between 'Seven Knots, LLC' (from the exhibit) or 'an institutional investor' (from the 8-K body) and the Company. While the current note holder is not explicitly identified as a related party, the highly favorable terms suggest a strong negotiating position for the investor.

Stakeholder Impact

• Shareholders: Significant potential for dilution due to the discounted conversion price and dilutive issuance provisions. The high cost of capital and punitive default terms could negatively impact shareholder value.
• Creditors (Note Holder): Highly favorable terms, including high interest, significant premiums, and strong remedies upon default, providing substantial protection and potential upside.
• Employees/Management: The financing provides short-term liquidity, potentially securing jobs, but the long-term financial health implications are concerning.
• CommLoan Inc.: Will receive an advance of $450,000, indicating progress towards its acquisition.

Next Steps

• Windtree Therapeutics, Inc. must file a resale registration statement on Form S-1 within 45 calendar days following November 25, 2025.
• The company intends to use $450,000 of the proceeds as an advance to CommLoan Inc. in connection with a letter of intent to acquire all of its securities.
• Interest payments on the notes are due on the 5th calendar day of each month.

Key Dates

Recommendation

The terms of this financing are extremely unfavorable for existing shareholders, characterized by a substantial original issue discount, high interest rates, highly dilutive conversion features (90% of lowest 20-day price), and punitive default clauses. This type of 'toxic' convertible debt typically signals severe financial distress and will likely lead to significant dilution and downward pressure on the stock price. The company is essentially selling future equity at a deep discount to secure immediate capital, which is a red flag for long-term shareholder value.

Keywords

Windtree Therapeutics, convertible note, debt financing, CommLoan Inc., acquisition, dilution, SEC filing, 8-K, capital raise, WINT, promissory note